Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by Advisory Services Network LLC

Advisory Services Network LLC boosted its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 543.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,603 shares of the company's stock after acquiring an additional 16,555 shares during the period. Advisory Services Network LLC's holdings in Moderna were worth $815,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. FMR LLC lifted its stake in shares of Moderna by 7.4% in the 4th quarter. FMR LLC now owns 18,664,634 shares of the company's stock worth $776,075,000 after acquiring an additional 1,282,469 shares during the period. Geode Capital Management LLC lifted its position in Moderna by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock valued at $300,219,000 after purchasing an additional 171,774 shares during the period. Invesco Ltd. boosted its holdings in Moderna by 24.3% in the 4th quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock valued at $208,169,000 after purchasing an additional 979,858 shares in the last quarter. Norges Bank purchased a new stake in Moderna in the 4th quarter valued at approximately $163,833,000. Finally, Charles Schwab Investment Management Inc. increased its position in Moderna by 9.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company's stock worth $97,472,000 after purchasing an additional 211,426 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MRNA has been the subject of several recent analyst reports. The Goldman Sachs Group cut Moderna from a "buy" rating to a "neutral" rating and reduced their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Citigroup initiated coverage on Moderna in a report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 target price for the company. Leerink Partners lowered their price target on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a research note on Thursday, January 16th. UBS Group cut their price target on shares of Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a report on Wednesday, February 19th. Finally, William Blair reissued a "market perform" rating on shares of Moderna in a report on Thursday. Four investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Moderna has a consensus rating of "Hold" and an average price target of $58.70.

Moderna Stock Performance

Moderna stock traded down $0.48 during midday trading on Friday, reaching $24.72. 6,678,250 shares of the company were exchanged, compared to its average volume of 7,288,295. The company has a market capitalization of $9.56 billion, a price-to-earnings ratio of -2.66 and a beta of 2.23. The firm's 50-day simple moving average is $30.84 and its 200-day simple moving average is $39.49. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $170.47.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.